Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245404 | 1.00 | LMNA (0.62) | LMNAMAPK1KEAP1NFE2L2BLM | |
| SCHEMBL245405 | 1.00 | LMNA (0.62) | LMNAMAPK1KEAP1NFE2L2BLM | |
| SCHEMBL11835765 | 0.94 | LMNA (0.56) | LMNAMAPK1KEAP1NFE2L2BLM | |
| D-Alanine SCHEMBL11208357 | 0.90 | LMNA (0.52) | LMNAMAPK1KEAP1NFE2L2BLM | |
| D-Alanine SCHEMBL11207612 | 0.90 | LMNA (0.52) | LMNAMAPK1KEAP1NFE2L2BLM | |
| Alanine SCHEMBL11209772 | 0.90 | LMNA (0.52) | LMNAMAPK1KEAP1NFE2L2BLM | |
| Alanine SCHEMBL11204313 | 0.90 | LMNA (0.52) | LMNAMAPK1KEAP1NFE2L2BLM | |
| D-Alanine SCHEMBL11496478 | 0.88 | LMNA (0.50) | LMNAMAPK1KEAP1NFE2L2BLM | |
| SCHEMBL275597 | 0.87 | LMNA (0.79) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL9000789 | 0.81 | LMNA (0.62) | LMNAMAPK1BLMNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113355367-B | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2024-03-26 | — | — | CN | claimed |
| US-20220281839-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2022-09-08 | — | — | US | claimed |
| CN-113355299-B | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2022-05-24 | — | — | CN | claimed |
| US-11306069-B2 | Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands | BIOPROJET (FR) | 2022-04-19 | — | — | US | claimed |
| CN-113355299-A | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-09-07 | — | — | CN | claimed |
| CN-113355367-A | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-09-07 | — | — | CN | claimed |
| CN-108410831-B | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-07-27 | — | — | CN | claimed |
| EP-3486243-B1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2020-04-15 | — | — | EP | claimed |
| EP-3486243-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | Bioprojet (FR) | 2019-05-22 | — | — | EP | claimed |
| US-20190144421-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2019-05-16 | — | — | US | claimed |
| CN-108410831-A | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2018-08-17 | — | — | CN | claimed |
| CN-102660471-B | Production of chiral alpha-hydroxy acid and its strain by using biological catalysis method | UNIV ZHEJIANG TECHNOLOGY | 2014-11-05 | — | — | CN | claimed |
| CN-102660470-B | Sinorhizobium fredii and its application in producing chiral alpha-hydroxy acid by biologically splitting alpha-hydroxy acid raceme | UNIV ZHEJIANG TECHNOLOGY | 2013-07-31 | — | — | CN | claimed |
| CN-102660471-A | Production of chiral alpha-hydroxy acid and its strain by using biological catalysis method | UNIV ZHEJIANG TECHNOLOGY | 2012-09-12 | — | — | CN | claimed |
| CN-102660470-A | Sinorhizobium fredii and its application in producing chiral alpha-hydroxy acid by biologically splitting alpha-hydroxy acid raceme | UNIV ZHEJIANG TECHNOLOGY | 2012-09-12 | — | — | CN | claimed |
| US-7985572-B2 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF SE (DE) | 2011-07-26 | — | — | US | claimed |
| EP-1599584-B1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF SE (DE) | 2009-07-01 | — | — | EP | claimed |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-17 | — | — | US | claimed |
| US-20060259999-A1 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-16 | — | — | US | claimed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12134608-B2 | Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands | BIOPROJET (FR) | 2024-11-05 | — | — | US | disclosed |
| CN-113355367-B | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-111757874-B | Methods for preparing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| CN-111051280-B | Process for preparing pyrrolidine compounds | 弗特克斯药品有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-108047033-B | Reaction device and method for preparing mandelic acid compound | 江西科苑生物药业有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230202999-A9 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| CN-110317212-B | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11465985-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220281839-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2022-09-08 | — | — | US | disclosed |
| US-11434201-B2 | Processes for preparing pyrrolidine compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220235025-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS INC (US) | 2022-07-28 | — | — | US | disclosed |
| CN-109689667-B | Porous chiral material and use thereof | 南开大学 | 2022-07-12 | — | — | CN | disclosed |
| EP-3527573-B9 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-113355299-B | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-108997253-B | Mandelic acid derivatives containing 1,3, 4-oxadiazole thioether and application thereof | 贵州大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-114394983-A | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11306069-B2 | Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands | BIOPROJET (FR) | 2022-04-19 | — | — | US | disclosed |
| EP-3661915-B1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | VERTEX PHARMA (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-113355299-A | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-09-07 | — | — | CN | disclosed |
| CN-113355367-A | Application of ketoacid reductase in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-09-07 | — | — | CN | disclosed |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-08-12 | — | — | US | disclosed |
| EP-3500582-B1 | POROUS CHIRAL MATERIALS AND USES THEREOF | UNIV NANKAI (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-108410831-B | Ketoacid reductase, gene, engineering bacterium and application in synthesis of chiral aromatic 2-hydroxy acid | 浙江工业大学 | 2021-07-27 | — | — | CN | disclosed |
| EP-3419974-B1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-05-05 | — | — | EP | disclosed |
| US-10975096-B2 | Synthesis of polycyclic-carbamoylpyridone compounds | GILEAD SCIENCES, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3783001-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| US-20200369608-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2020-11-26 | — | — | US | disclosed |
| EP-3720849-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111757874-A | Method for producing modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3527573-B1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200223866-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3661915-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111051280-A | Process for producing pyrrolidine compound | 弗特克斯药品有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3486243-B1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2020-04-15 | — | — | EP | disclosed |
| CN-110317212-A | The synthesis of polycyclic carbamoylpyridone compound | 吉利德科学公司 | 2019-10-11 | — | — | CN | disclosed |
| EP-3527573-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | ASCENEURON S A (CH) | 2019-07-09 | — | — | US | disclosed |
| EP-3500582-A1 | POROUS CHIRAL MATERIALS AND USES THEREOF | Nankai University (CN) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019113476-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-3486243-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | Bioprojet (FR) | 2019-05-22 | — | — | EP | disclosed |
| US-20190144421-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2019-05-16 | — | — | US | disclosed |
| CN-106470975-B | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-109689667-A | Porous chiral material and use thereof | 南开大学 | 2019-04-26 | — | — | CN | disclosed |
| WO-2019028228-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3419974-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| CN-108997253-A | Mandelic acid derivatives and its application of the one kind containing \" 1,3,4- oxadiazoles thioether \ | 贵州大学 | 2018-12-14 | — | — | CN | disclosed |
| CN-108884081-A | The method for separating the enantiomer of bridged piperazine derivatives | 阿森纽荣股份公司 | 2018-11-23 | — | — | CN | disclosed |
| US-10113025-B2 | Functionalized ketone-aldehyde condensation resins | EVONIK DEGUSSA GMBH (DE) | 2018-10-30 | — | — | US | disclosed |
| WO-2018035660-A1 | POROUS CHIRAL MATERIALS AND USES THEREOF | NANKAI UNIVERSITY (CN) | 2018-03-01 | — | — | WO | disclosed |
| US-20180022757-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2018-01-25 | — | — | US | disclosed |
| WO-2017144635-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| EP-3157933-A2 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| CN-106470975-A | Synthesis of Polycyclic Carbamoylpyridone Compounds | 吉利德科学公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106046281-A | FUNCTIONALIZED KETONE-ALDEHYDE CONDENSATION RESINS | 赢创德固赛有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-20160289366-A1 | FUNCTIONALIZED KETONE-ALDEHYDE CONDENSATION RESINS | EVONIK DEGUSSA GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150368264-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-24 | — | — | US | disclosed |
| WO-2015195656-A2 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | GILEAD SCIENCES ,INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150125928-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC | 2015-05-07 | — | — | US | disclosed |
| EP-2327767-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | disclosed |
| CN-102170864-B | Treatment of Respiratory Diseases | PULMAGEN THERAPUTICS INFLAMMATION LTD | 2015-04-01 | — | — | CN | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| CN-102660471-B | Production of chiral alpha-hydroxy acid and its strain by using biological catalysis method | UNIV ZHEJIANG TECHNOLOGY | 2014-11-05 | — | — | CN | disclosed |
| US-8815569-B2 | Methods for preserving and/or storing cells having a nitrilase or nitrile hydratase activity | BASF SE (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8778651-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| CN-102660624-B | Alpha-hydroxy acid deracemisation method and strain | UNIV ZHEJIANG TECHNOLOGY | 2013-10-16 | — | — | CN | disclosed |
| CN-102660470-B | Sinorhizobium fredii and its application in producing chiral alpha-hydroxy acid by biologically splitting alpha-hydroxy acid raceme | UNIV ZHEJIANG TECHNOLOGY | 2013-07-31 | — | — | CN | disclosed |
| US-20130177949-A1 | NITRILASES | VERENIUM CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177949-A1 | NITRILASES | VERENIUM CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8334125-B2 | Nucleic acids encoding nitrilases | VERENIUM CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334125-B2 | Nucleic acids encoding nitrilases | VERENIUM CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2222272-B1 | Respiratory disease treatment | PULMAGEN THERAPEUTICS INFLAMMATION LTD (GB) | 2012-11-07 | — | — | EP | disclosed |
| CN-102660471-A | Production of chiral alpha-hydroxy acid and its strain by using biological catalysis method | UNIV ZHEJIANG TECHNOLOGY | 2012-09-12 | — | — | CN | disclosed |
| CN-102660624-A | Alpha-hydroxy acid deracemisation method and strain | UNIV ZHEJIANG TECHNOLOGY | 2012-09-12 | — | — | CN | disclosed |
| CN-102660470-A | Sinorhizobium fredii and its application in producing chiral alpha-hydroxy acid by biologically splitting alpha-hydroxy acid raceme | UNIV ZHEJIANG TECHNOLOGY | 2012-09-12 | — | — | CN | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012007814-A2 | THREE COMPONENT CO-CRYSTAL FORMATION BETWEEN DIASTEREOMERIC MIXTURES OF 3-ALKYL-4-((S)-1'PHENYLETHYLAMINO) BUTANOIC ACID AND OPTICALLY PURE 1, 1'-BI-2-NAPHTHOL | LUPIN LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110263839-A1 | Nucleic Acids Encoding Nitrilases | VERENIUM CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263839-A1 | Nucleic Acids Encoding Nitrilases | VERENIUM CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| CN-102170864-A | Treatment of Respiratory Diseases | ARGENTA DISCOVERY LTD | 2011-08-31 | — | — | CN | disclosed |
| US-7993901-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| US-7993901-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| US-7985572-B2 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF SE (DE) | 2011-07-26 | — | — | US | disclosed |
| EP-2327767-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2327766-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2327765-A1 | Nitrilases | Verenium Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2319919-A1 | Nitrilases | Verenium Corporation (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2222272-A1 | RESPIRATORY DISEASE TREATMENT | Pulmagen Therapeutics (Inflammation) Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-20100009426-A1 | synthetic or recombinant polypeptide having a nitrilase activity; have increased activity and stability at increased pH and temperature | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-7608445-B1 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| EP-1599584-B1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF SE (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1578910-A4 | NITRILASES | VERENIUM CORP (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-17 | — | — | US | disclosed |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| EP-1236714-B1 | ACETALSULFONATE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING STYRENE OXIDE DERIVATIVE | MITSUBISHI RAYON CO (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060259999-A1 | Modified nitrilases and their use in methods for the production of carboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-16 | — | — | US | disclosed |
| US-7094799-B2 | A single, thermodynamical stable crystal structure, is crystallized from a cooled and agitated solvent solution, analgesic drug for reducing pain | DOV PHARMACEUTICAL, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1562900-A4 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV PHARMACEUTICAL INC (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060110808-A1 | Methods for preserving and/or storing cellshaving a nitrilase or nitrile hydratase avtivity | BASF AKTIENGESELLSCHAFT | 2006-05-25 | — | — | US | disclosed |
| CN-1735594-A | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | CN | disclosed |
| CN-1235875-C | Substituted alpha-hydroxy acid caspase inhibitors and uses thereof | CYTOVIA INC (US) | 2006-01-11 | — | — | CN | disclosed |
| EP-1599584-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1578910-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1562900-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV Pharmaceutical Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004076655-A1 | MODIFIED NITRILASES AND THEIR USE IN METHODS FOR THE PRODUCTION OF CARBOXYLIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-6743944-B1 | FORMING DIASTEREOMERIC SALT OF RACEMIC 4-AMINO-2-METHYL-BUTANE-1-OL AND OPTICALLY ACTIVE ORGANIC ACID; CRYSTALLI-ZATION; ALKALI SOLUTION DECOMPOSITION | MITSUBISHI RAYON CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| WO-2004043920-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | EUTHYMICS BIOSCIENCE, INC. | 2004-05-27 | — | — | US | disclosed |
| EP-0838448-B1 | Process for the separation of a mixture of enantiomers | DSM IP ASSETS BV (NL) | 2004-04-21 | — | — | EP | disclosed |
| US-6642395-B1 | Esterifying mandelic acid derivative; protecting hydroxyl group and reducing ester; sulfonating and epoxidizing | MITSUBISHI RAYON CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-0915080-B1 | Process for preparing optically active amines and optically active carboxylic acids, and intermediates for preparation | YAMAKAWA CHEMICAL IND (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6495522-B1 | PREVENTING APOPTOTIC CELL DEATH IN WHICH THE LOSS OF CELLS, TISSUES OR ENTIRE ORGANS OCCURS | CYTOVIA, INC. | 2002-12-17 | — | — | US | disclosed |
| CN-1382119-A | Substituted alpha-hydroxy acid caspase inhibitors and uses thereof | CYTOVIA INC (US) | 2002-11-27 | — | — | CN | disclosed |
| US-6465684-B2 | DIASTEREOMER COMPLEX OF AT LEAST THREE COMPOUNDS, AT LEAST ONE IS A RESOLVING AGENT IN OPTICALLY ACTIVE FORM, AND AT LEAST ONE IS AN ENANTIOMER IN OPTICALLY ACTIVE FORM; RAPID SEPARATION | DSM N.V. (NL) | 2002-10-15 | — | — | US | disclosed |
| EP-1236714-A1 | ACETALSULFONATE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING STYRENE OXIDE DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-1219593-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINOALCOHOL | Mitsubishi Rayon Co., Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1212295-A1 | SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6342636-B1 | REACTION OF ARYLALKYLAMINE WITH NAPHTHYLGLYCOLIC ACID AND DECOMPOSITION A DIASTEROMER SALT TO OBTAIN AN ENANTIOMORPH | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-01-29 | — | — | US | disclosed |
| US-20010051747-A1 | Process for the separation of a mixture of enantiomers | DSM N.V. | 2001-12-13 | — | — | US | disclosed |
| US-6235927-B1 | OPTICAL RESOLUTION OF ENANTIOMORPHS OF COMPLEXES | DSM N.V. (NL) | 2001-05-22 | — | — | US | disclosed |
| WO-2001016093-A1 | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0915080-A1 | Process for preparing optically active amines and optically active carboxylic acids, and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1999-05-12 | — | — | EP | disclosed |
| EP-0838448-A1 | Process for the separation of a mixture of enantiomers | DSM N.V. (NL) | 1998-04-29 | — | — | EP | disclosed |
| EP-0816316-A1 | PROCESS FOR PRODUCING 1,2-ETHANEDIOL DERIVATIVES | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0146269-B1 | HETERO-POLYCYCLIC AROMATIC COMPOUND | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-01-03 | — | — | EP | disclosed |
| US-4650882-A | Dyes having two 5-membered lactone rings fused to a central cyclohexa-1.4-diene nucleus | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-03-17 | — | — | US | disclosed |
| EP-0146269-A2 | Hetero-polycyclic aromatic compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-26 | — | — | EP | disclosed |
| EP-0033583-B1 | DYESTUFFS COMPRISING TWO 5-MEMBERED HETEROCYCLIC NUCLEI FUSED TO A CENTRAL CYCLOHEXADIENE NUCLEUS, PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR COLOURING SYNTHETIC TEXTILE MATERIALS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
| EP-0023080-B1 | SUBSTITUTED 2,7-DIOXO-2,7-DIHYDROBENZO(1:2-B; 5,6-B1)DIFURAN OR DIPYRROLE DYESTUFFS, PROCESSES FOR THEIR PREPARATION AND THEIR USE FOR THE COLOURATION OF AROMATIC POLYESTER TEXTILE MATERIALS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-07-27 | — | — | EP | disclosed |
| US-4333877-A | Substituted 2,7-dioxo-2,7-dihydrobenzo[1:2-b; 5:6-b1 ]difuran or -dipyrrole dyestuffs, their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-06-08 | — | — | US | disclosed |
| EP-0033583-A1 | Dyestuffs comprising two 5-membered heterocyclic nuclei fused to a central cyclohexadiene nucleus, processes for their preparation and their use for colouring synthetic textile materials | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-12 | — | — | EP | disclosed |
| EP-0023080-A1 | Substituted 2,7-dioxo-2,7-dihydrobenzo(1:2-b; 5,6-b1)difuran or dipyrrole dyestuffs, processes for their preparation and their use for the colouration of aromatic polyester textile materials | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-01-28 | — | — | EP | disclosed |
| US-4218380-A | OXIDATION OF THE A-HYDROXY-ARYLACETIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-19 | — | — | US | disclosed |
| US-4091214-A | ALPHA-HYDROXY CARBOXYLIC ACID | ELI LILLY AND COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-4091214-A | ALPHA-HYDROXY CARBOXYLIC ACID | ELI LILLY AND COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (33 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368264-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | CPS1, SDHA, DHPS | LMNA 2030/4885MAPK1 4044/4885KEAP1 2541/4885 |
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | LMNA 1689/4885MAPK1 4459/4885KEAP1 1264/4885 |
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | LMNA 3952/4885MAPK1 2771/4885KEAP1 3724/4885 |
| US-12466835-B1 | Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same | FNTA, SF3B1, SF3A1 | LMNA 1318/4885MAPK1 2101/4885KEAP1 473/4885 |
| US-20200223866-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | CPS1, SDHA, DHPS | LMNA 2030/4885MAPK1 4044/4885KEAP1 2541/4885 |
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | CYP3A5, CYP4Z1, HTR5A | LMNA 1321/4885MAPK1 1627/4885KEAP1 273/4885 |
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | LMNA 780/4885MAPK1 924/4885KEAP1 483/4885 |
| US-12384757-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | LMNA 780/4885MAPK1 924/4885KEAP1 483/4885 |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | LMNA 3683/4885MAPK1 1948/4885KEAP1 817/4885 |
| US-20190144421-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | HRH4, HRH3, HRH1 | LMNA 4746/4885MAPK1 3692/4885KEAP1 1280/4885 |
| US-20200369608-A1 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | MTAP, PRMT5, TET3 | LMNA 1837/4885MAPK1 1217/4885KEAP1 4489/4885 |
| US-20220235025-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | LMNA 780/4885MAPK1 924/4885KEAP1 483/4885 |
| US-20110263839-A1 | Nucleic Acids Encoding Nitrilases | RNGTT, NSUN2, DNTT | LMNA 1303/4885MAPK1 4328/4885KEAP1 3317/4885 |
| US-20240043398-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | LMNA 780/4885MAPK1 924/4885KEAP1 483/4885 |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | LMNA 1827/4885MAPK1 366/4885KEAP1 1258/4885 |
| US-20180022757-A1 | SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS | CPS1, SDHA, DHPS | LMNA 2030/4885MAPK1 4044/4885KEAP1 2541/4885 |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | LMNA 1689/4885MAPK1 4459/4885KEAP1 1264/4885 |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | ASPH, AHSA1, DNPH1 | LMNA 697/4885MAPK1 2286/4885KEAP1 2503/4885 |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | LMNA 1689/4885MAPK1 4459/4885KEAP1 1264/4885 |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | LMNA 3445/4885MAPK1 2625/4885KEAP1 842/4885 |
| US-20010051747-A1 | Process for the separation of a mixture of enantiomers | EPHX2, VKORC1, ALDH1A2 | LMNA 270/4885MAPK1 4593/4885KEAP1 401/4885 |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | LMNA 4199/4885MAPK1 1813/4885KEAP1 1024/4885 |
| US-11434201-B2 | Processes for preparing pyrrolidine compounds | MTAP, PRMT5, TET3 | LMNA 1837/4885MAPK1 1217/4885KEAP1 4489/4885 |
| US-20230202999-A9 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | LMNA 780/4885MAPK1 924/4885KEAP1 483/4885 |
| US-11465985-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | LMNA 3683/4885MAPK1 1948/4885KEAP1 817/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | LMNA 3445/4885MAPK1 2625/4885KEAP1 842/4885 |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | RNGTT, NSUN2, NSUN3 | LMNA 1395/4885MAPK1 4287/4885KEAP1 2794/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | LMNA 219/4885MAPK1 1200/4885KEAP1 3938/4885 |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | CPN1, AKR1C3, AHCY | LMNA 1994/4885MAPK1 2896/4885KEAP1 1368/4885 |
| US-20220281839-A1 | BENZIMIDAZOLE DERIVATIVES AS DUAL HISTAMINE H1 AND HISTAMINE H4 RECEPTOR LIGANDS | HRH4, HRH3, HRH1 | LMNA 4626/4885MAPK1 3796/4885KEAP1 1128/4885 |
| US-12134608-B2 | Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands | HRH4, HRH3, HRH1 | LMNA 4626/4885MAPK1 3796/4885KEAP1 1128/4885 |
| US-10975096-B2 | Synthesis of polycyclic-carbamoylpyridone compounds | CPS1, SDHA, DHPS | LMNA 2030/4885MAPK1 4044/4885KEAP1 2541/4885 |
| US-11306069-B2 | Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands | HRH4, HRH3, HRH1 | LMNA 4746/4885MAPK1 3692/4885KEAP1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.